Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival Is Possible

Cureus
doi 10.7759/cureus.419
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cureus, Inc.

Related search

Concurrent Presence of ALK Rearrangement and MET Mutation in Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

The Profile of Lung Adenocarcinoma Patients With Positive EGFR Mutation

Green Medical Journal
2020English

Second-Line Erlotinib in an EGFR Mutation-Negative Patient With Non-Small-Cell Lung Cancer

Current Oncology
Oncology
2012English

Predictive Factors in Patients With EGFR Mutation‑negative Non‑small Cell Lung Cancer Treated With Erlotinib

Oncology Letters
Cancer ResearchOncology
2014English

MA27.07 Lung Adenocarcinoma Harboring BRAF G469V Mutation Is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Presence of the Minor EGFR T790M Mutation Is Associated With Drug-Sensitive EGFR Mutations in Lung Adenocarcinoma Patients

Oncology Reports
MedicineCancer ResearchOncology
2014English

Mutation Profile of Resected EGFR‐Mutated Lung Adenocarcinoma by Next‐Generation Sequencing

Oncologist
Cancer ResearchMedicineOncology
2019English

Relationship Between EGFR Mutation and Computed Tomography Characteristics of the Lung in Patients With Lung Adenocarcinoma

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2018English

A Heterochronic Genetic Change From an EGFR Mutation to an ALK Rearrangement in a Patient With Lung Adenocarcinoma: A Case Report

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy